Abstract 407P
Background
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker to monitor molecular residual disease (MRD) in solid tumors after curative-intent treatment. Since imaging and plasma-derived protein biomarkers both have limited sensitivity and specificity, ctDNA could complement conventional methods to guide post-operative monitoring and treatment plans for patients. This study evaluated the clinical utility of our tumor-informed, personalized ctDNA assay to identify patients at high risk of recurrence.
Methods
This prospective multi-center study enrolled 510 patients with liver, colorectal, breast, lung, gastric and ovarian cancers who were eligible for curative-intent surgery. Genomic DNA extracted from tumor tissue and paired white blood cells was subjected to massively parallel sequencing of 150 cancer-related genes. A proprietary algorithm ranked the top somatic mutations unique to each patient, which were then used to detect ctDNA in serial plasma samples.
Results
The pre-operative detection rate of ctDNA was 91%, 97%, 62%, 65%, 57%, and 46% for colorectal, liver, lung, ovarian, high-risk breast cancer, and gastric cancer respectively; the specificity was >99% as ctDNA was not detected in the plasma from healthy donors. Our interim analysis after a 20-month follow-up demonstrated that 88% of patients with recurrence and/or metastasis (35/40) had ctDNA detected in their post-operative plasma samples. On average, such ctDNA detection was 5 months (up to 13 months) earlier than clinical diagnosis. Post-operative ctDNA was also found as an independent prognostic factor for disease-free survival in multiple types of cancer (p<0.001).
Conclusions
K-Track™ assay provides longitudinal ctDNA monitoring that showed clinical utility in predicting disease-free survival and early relapse detection in cancer patients. This simplified and cost-effective approach enables MRD monitoring to be more accessible in routine clinical practice in developing countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute, Ho Chi Minh City, Vietna.
Funding
Gene Solutions JSC, Ho Chi Minh city, Vietnam.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract